Another Chinese Communist virus vaccine is here, 95% effective, expected to be approved for use by the end of the year

French pharmaceutical company Sanofi (Sanofi) and British pharmaceutical company GlaxoSmithKline (GSK) jointly developed the vaccine, Monday (17) announced the phase 2 clinical results, showing that the vaccine in the adult group can achieve strong immune effect, the next few months will start the final phase of clinical trials, hope to obtain approval for use before the end of the year.

The clinical trial involved 722 volunteers from the United States and Honduras, aged 18 to 95 years old.

Their second dose produced 95 to 100 percent immunity, producing neutralizing antibodies consistent with those naturally produced in infected individuals. Sanofi said the vaccine has no safety concerns and can be used with adjuvants to boost immunity.

The final phase of clinical trials will begin in the coming weeks, with more than 35,000 volunteers recruited worldwide. The drug company plans to produce 1 billion doses of the vaccine annually, and has already signed supply agreements with the United States, Canada and some developing countries.